Moonlake Immunotherapeutics (MLTX) Stock Price, Quote & News - Mboum

Company Profile

MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

Industry: Biotechnology

Sector: Healthcare

Phone: 41 415108022

Website: www.moonlaketx.com

Address:

Dorfstrasse 29, Zug, Switzerland

Bigbadjohn89 Oct. 25 at 3:43 PM

0 · Reply

Bigbadjohn89 Oct. 25 at 3:36 PM

0 · Reply

Matteus91 Oct. 25 at 3:27 PM

0 · Reply

sh3r1ock Oct. 25 at 3:02 PM

0 · Reply

Godsgrace2025 Oct. 25 at 1:03 PM

0 · Reply

slickinvest Oct. 25 at 12:53 PM

0 · Reply

AXMO Oct. 25 at 12:29 PM

0 · Reply

ROLEXKING420 Oct. 25 at 12:09 PM

0 · Reply

MoneyGroupLLC Oct. 25 at 9:48 AM

Enter: $MLTX Calls Strike Price: $10 Expiry Date: NOV 21 2025 Buy in Price: $0.80 - $0.80 Sell Price: $1.18 Profit : +47% (Turn every $1 into $1.47) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

Bgggggggie Oct. 25 at 9:28 AM

$MLTX all you fuckers want this to rise but only buy calls. This stasis is on you.

1 · Reply

Latest News on MLTX

MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny After Reporting Disappointing Phase 3 Trial Data For Lead Drug Candidate -- Hagens Berman

Oct 14, 2025, 12:03 PM EDT - 11 days ago

MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny After Reporting Disappointing Phase 3 Trial Data For Lead Drug Candidate -- Hagens Berman

MLTX SECURITIES NOTICE: MoonLake Immunotherapeutics Securities Fraud Investigation is Pending – Contact BFA Law if You Lost Money

Oct 10, 2025, 8:18 AM EDT - 15 days ago

MLTX SECURITIES NOTICE: MoonLake Immunotherapeutics Securities Fraud Investigation is Pending – Contact BFA Law if You Lost Money

MOONLAKE IMMUNOTHERAPEUTICS REMINDER: Bragar Eagel & Squire, P.C. Urges Investors in MoonLake to Contact the Firm Regarding the Ongoing Investigation on Behalf of Stockholders

Oct 9, 2025, 3:18 PM EDT - 15 days ago

MOONLAKE IMMUNOTHERAPEUTICS REMINDER: Bragar Eagel & Squire, P.C. Urges Investors in MoonLake to Contact the Firm Regarding the Ongoing Investigation on Behalf of Stockholders

MLTX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Oct 8, 2025, 10:15 AM EDT - 17 days ago

MLTX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

MLTX INQUIRY NOTICE: MoonLake Immunotherapeutics Hit with Securities Fraud Investigation Due to Drug Trial Results -- Contact BFA Law

Oct 8, 2025, 7:36 AM EDT - 17 days ago

MLTX INQUIRY NOTICE: MoonLake Immunotherapeutics Hit with Securities Fraud Investigation Due to Drug Trial Results -- Contact BFA Law

MLTX Investors Have Opportunity to Join MoonLake Immunotherapeutics Fraud Investigation with the Schall Law Firm

Oct 6, 2025, 8:59 PM EDT - 18 days ago

MLTX Investors Have Opportunity to Join MoonLake Immunotherapeutics Fraud Investigation with the Schall Law Firm

MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX

Oct 6, 2025, 8:59 PM EDT - 18 days ago

MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX

MoonLake Immunotherapeutics Investors Should Contact Block & Leviton to Find Out How They Might Recover Losses Through The Firm's Investigation

Oct 6, 2025, 2:35 PM EDT - 18 days ago

MoonLake Immunotherapeutics Investors Should Contact Block & Leviton to Find Out How They Might Recover Losses Through The Firm's Investigation

MLTX SHAREHOLDER NOTICE: MoonLake Immunotherapeutics Investigated for Securities Fraud after 90% Stock Drop – Contact BFA Law

Oct 6, 2025, 8:36 AM EDT - 19 days ago

MLTX SHAREHOLDER NOTICE: MoonLake Immunotherapeutics Investigated for Securities Fraud after 90% Stock Drop – Contact BFA Law

Top 3 Health Care Stocks That Are Preparing To Pump In Q4

Oct 6, 2025, 6:23 AM EDT - 19 days ago

Top 3 Health Care Stocks That Are Preparing To Pump In Q4

MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Oct 5, 2025, 11:43 PM EDT - 19 days ago

MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

MLTX LEGAL NOTICE: MoonLake Immunotherapeutics Faces Securities Fraud Investigation due to Drug Trial Results – Contact BFA Law if You Lost Money

Oct 4, 2025, 7:07 AM EDT - 21 days ago

MLTX LEGAL NOTICE: MoonLake Immunotherapeutics Faces Securities Fraud Investigation due to Drug Trial Results – Contact BFA Law if You Lost Money

MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX

Oct 1, 2025, 3:02 PM EDT - 23 days ago

MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX

MLTX BREAKING NEWS: BFA Law is Investigating MoonLake Immunotherapeutics (NASDAQ: MLTX) for Securities Fraud after Stock Drops 90% on Drug Trial Results, Investors Urged to Contact the Firm

Sep 29, 2025, 6:20 PM EDT - 25 days ago

MLTX BREAKING NEWS: BFA Law is Investigating MoonLake Immunotherapeutics (NASDAQ: MLTX) for Securities Fraud after Stock Drops 90% on Drug Trial Results, Investors Urged to Contact the Firm

MoonLake Immunotherapeutics - Special Call

Sep 29, 2025, 6:07 PM EDT - 25 days ago

MoonLake Immunotherapeutics - Special Call

MoonLake Immunotherapeutics Stock Plummets After Phase 3 Data Readouts

Sep 29, 2025, 2:44 PM EDT - 25 days ago

MoonLake Immunotherapeutics Stock Plummets After Phase 3 Data Readouts

BREAKING: MoonLake Immunotherapeutics Shares Down Over 85%; Investors Should Contact Block & Leviton to Potentially Recover Losses

Sep 29, 2025, 10:53 AM EDT - 26 days ago

BREAKING: MoonLake Immunotherapeutics Shares Down Over 85%; Investors Should Contact Block & Leviton to Potentially Recover Losses

Moonlake: What's Happening With MLTX Stock?

Sep 29, 2025, 9:05 AM EDT - 26 days ago

Moonlake: What's Happening With MLTX Stock?

MoonLake shares crash 88% after mixed trial results raise doubts over skin drug

Sep 29, 2025, 9:02 AM EDT - 26 days ago

MoonLake shares crash 88% after mixed trial results raise doubts over skin drug

Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Sep 29, 2025, 8:06 AM EDT - 26 days ago

Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab

Sep 28, 2025, 12:04 PM EDT - 27 days ago

MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab

2 Logical Mid-Cap Biotech Buyout Targets

Aug 27, 2025, 12:50 PM EDT - 2 months ago

2 Logical Mid-Cap Biotech Buyout Targets

MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

Aug 5, 2025, 7:00 AM EDT - 2 months ago

MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest

Jun 3, 2025, 3:08 PM EDT - 5 months ago

MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest

Merck held talks to buy biotech MoonLake for over $3 billion, FT reports

Jun 2, 2025, 5:08 PM EDT - 5 months ago

Merck held talks to buy biotech MoonLake for over $3 billion, FT reports

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

May 12, 2025, 4:00 PM EDT - 5 months ago

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

Apr 25, 2025, 4:05 PM EDT - 6 months ago

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

MoonLake Immunotherapeutics: A Buy At Dips

Apr 8, 2025, 3:31 AM EDT - 7 months ago

MoonLake Immunotherapeutics: A Buy At Dips

MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

Apr 3, 2025, 7:00 AM EDT - 7 months ago

MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

Feb 26, 2025, 7:00 AM EST - 8 months ago

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced Upon

Jan 17, 2025, 6:03 PM EST - 10 months ago

MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced Upon

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

Jan 8, 2025, 7:00 AM EST - 10 months ago

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

Sep 9, 2024, 7:00 AM EDT - 1 year ago

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward

Jul 18, 2024, 2:19 PM EDT - 1 year ago

MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

May 16, 2024, 8:00 AM EDT - 1 year ago

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

MoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market Expansion

May 12, 2024, 8:37 AM EDT - 1 year ago

MoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market Expansion

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

May 7, 2024, 8:00 AM EDT - 1 year ago

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions

Apr 10, 2024, 7:00 AM EDT - 1 year ago

MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions

MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions

Apr 10, 2024, 7:00 AM EDT - 1 year ago

MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

Mar 10, 2024, 12:00 PM EDT - 1 year ago

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

Bigbadjohn89 Oct. 25 at 3:43 PM

0 · Reply

Bigbadjohn89 Oct. 25 at 3:36 PM

0 · Reply

Matteus91 Oct. 25 at 3:27 PM

0 · Reply

sh3r1ock Oct. 25 at 3:02 PM

0 · Reply

Godsgrace2025 Oct. 25 at 1:03 PM

0 · Reply

slickinvest Oct. 25 at 12:53 PM

0 · Reply

AXMO Oct. 25 at 12:29 PM

0 · Reply

ROLEXKING420 Oct. 25 at 12:09 PM

0 · Reply

MoneyGroupLLC Oct. 25 at 9:48 AM

Enter: $MLTX Calls Strike Price: $10 Expiry Date: NOV 21 2025 Buy in Price: $0.80 - $0.80 Sell Price: $1.18 Profit : +47% (Turn every $1 into $1.47) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

Bgggggggie Oct. 25 at 9:28 AM

$MLTX all you fuckers want this to rise but only buy calls. This stasis is on you.

1 · Reply

MoneyGroupLLC Oct. 25 at 1:41 AM

Enter: $MLTX NOV 21 2025 $10 CALLS Buy in Price: $0.72 - $0.85 Take Profit: $0.89 Stop Bleeding: $0.63 ROI Potential: 24% https://moneygroup.us/

0 · Reply

GeneMachine Oct. 25 at 1:35 AM

$MLTX don't let go and don't give up! Get up and dance the back pain away! You got a reason to live! CFO Matthias Bodenstedt and MoonLake Fam I LOVE YOU!!! https://youtu.be/0sSZBlA7ygw?si=b4ZVH9lLuc09PaUa

0 · Reply

jayjaynyc Oct. 25 at 12:39 AM

$MLTX Short interest went down so shorts covered a bit from 10/1 to 10/15:

0 · Reply

MerylCreep Oct. 24 at 11:05 PM

$MLTX Life of the party

2 · Reply

Stocklord6 Oct. 24 at 10:49 PM

$MLTX lawsuits rolling in. Stock has to recover or the executives could face serious jail time.

1 · Reply

Bexthehex Oct. 24 at 10:24 PM

$MLTX happy weekend friends !

0 · Reply

ROLEXKING420 Oct. 24 at 10:22 PM

$MLTX WOW GREEN AFTERHOURS!!!

0 · Reply

Carbarcarbar Oct. 24 at 9:06 PM

$MLTX just wait till we see 20 million vol how fast it will go

0 · Reply

ROLEXKING420 Oct. 24 at 9:02 PM

$MLTX I might go to $35.00 on the new PR coming. I think!

2 · Reply

RunnerSignals Oct. 24 at 8:38 PM

Dip-to-Rip Squad Strikes Back $FCX $MO $MLTX $NPWR $TELO started red but ripped green by the close! Buyers showed up late

0 · Reply

TDMF123 Oct. 24 at 8:12 PM

$MLTX I know something positive is coming on this one. Something is brewing and I’m not a seller.

0 · Reply

Ribonka68 Oct. 24 at 8:02 PM

$MLTX no volume today. All is fine

0 · Reply